Google Cloud said on the 4th that Syntekabio, a domestic artificial intelligence (AI) new drug development corporations, built a cloud environment based on Google Kubernetes Engine (GKE). With this transition, Syntekabio improved infrastructure efficiency and laid the groundwork for global market expansion.
Syntekabio is a technology corporations that uses AI to discover and optimize drug candidates, operating its own platforms "DeepMatcher" and "Neo-ALS," among others. Through this collaboration, it moved its existing AWS environment to GKE and strengthened AI model training and data analysis performance using GPUs.
It also applied Google Cloud's security features to build a data protection framework on par with global pharmaceutical companies. The two companies plan to broaden their cooperation in AI-driven new drug development going forward.
Chief Executive Jeong Jong-seon of Syntekabio said, "Google Cloud's infrastructure and AI capabilities will be a great boost to Syntekabio's global expansion," adding, "We will accelerate innovation in AI-based new drug development."
Google Cloud Korea President Ji Ki-seong said, "We will continue to support Syntekabio so it can secure technological competitiveness in the global market."